Q2 2026 13F · SEC CIK 1601086

Armistice Capital, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $3.6B
Reported positions: 323
Top holdings a year, 3 yrs: +23.9%
Assets under management: $4.7B

Armistice Capital, LLC is a hedge fund that reported 323 positions worth $3.6B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Madrigal Pharmaceuticals Inc (MDGL, 4.3%), Supernus Pharmaceuticals (SUPN, 3.4%), Cytokinetics Inc (CYTK, 2.8%). A portfolio copying its top holdings returned 23.9% a year over the last 3 years, against 20.4% for the S&P 500.

Armistice Capital, LLC holdings largest 50 of 323 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Armistice Capital, LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
MDGLMadrigal Pharmaceuticals Inc	4.3%	4.6%	288,000	+8.9%	$154.6M
SUPNSupernus Pharmaceuticals	3.4%	3.2%	2,646,201	+39.6%	$123.1M
CYTKCytokinetics Inc	2.8%	1.7%	1,201,342	+57.1%	$102.3M
INCYIncyte Corp	2.8%	2.0%	900,005	+37.0%	$102.0M
NBIXNeurocrine Biosciences Inc	2.5%	3.1%	535,838	-26.0%	$90.3M
TVTXTravere Therapeutics Inc	2.5%	4.8%	1,572,539	-67.9%	$89.3M
AGIOAgios Pharmaceuticals Inc	2.5%	3.0%	2,400,000	-11.6%	$89.1M
PTCTPtc Therapeutics Inc	2.4%	4.7%	1,071,395	-48.4%	$87.4M
UNHUnitedhealth Group Inc Com	2.1%	1.3%	183,000	+23.6%	$76.1M
FRPTFreshpet Inc	2.1%	2.1%	1,260,702	+15.3%	$74.5M
DYNDyne Therapeutics Inc	1.9%	1.9%	3,087,226	-2.8%	$68.6M
AMZNAmazon Com Inc Com	1.9%	1.8%	284,562	+8.6%	$67.8M
IMVTImmunovant Inc	1.9%	2.9%	1,736,000	-51.3%	$66.9M
RIGLRigel Pharmaceuticals Inc	1.8%	1.1%	1,672,000	+30.6%	$65.4M
TMOThermo Fisher Scientific Inc	1.7%	1.5%	122,480	+33.9%	$61.4M
IRWDIronwood Pharmaceuticals Inc Com	1.6%	1.7%	13,932,000	-7.3%	$58.7M
HRMYHarmony Biosciences Hldgs in	1.6%	1.5%	1,564,000	-3.7%	$56.9M
REGNRegeneron Pharmaceuticals	1.5%	0.9%	89,809	+148.6%	$56.0M
NKTRNektar Therapeutics	1.4%	1.4%	724,000	+25.3%	$50.5M
MLYSMineralys Therapeutics Inc	1.3%	1.1%	1,736,000	+47.6%	$46.8M
SNYNFSanofi SA	1.3%	—	1,064,000	—	$45.4M
IMCRImmunocore Hldgs PLC	1.3%	1.2%	1,428,000	+20.2%	$45.3M
GOOGLAlphabet Inc	1.3%	1.1%	126,494	+6.7%	$45.2M
SLDBSolid Bioscience Inc.	1.2%	0.8%	4,278,000	+33.7%	$42.7M
MDBMongodb Inc	1.2%	0.9%	125,172	+16.7%	$42.0M
KURAKura Oncology Inc	1.1%	1.0%	3,678,000	-1.6%	$40.3M
XRAYDentsply Sirona Inc	1.1%	1.1%	3,672,000	+22.4%	$39.0M
UBERUber Technologies Inc	1.0%	1.2%	497,908	-4.0%	$35.9M
AXGNAxogen Inc	1.0%	1.0%	775,000	-17.2%	$35.8M
IRONDisc Medicine Inc	0.9%	1.1%	460,000	-14.2%	$33.6M
GTLBGitLab Inc	0.9%	0.7%	1,074,141	+4.4%	$32.8M
FIVNFive9 Inc	0.9%	0.8%	1,536,000	-3.5%	$32.7M
HUBSHubspot Inc	0.9%	1.0%	178,047	+38.5%	$32.5M
ALGNAlign Technology Inc	0.8%	0.9%	180,286	+14.1%	$30.4M
MSFTMicrosoft Corp	0.8%	—	80,581	—	$30.1M
OFIXOrthofix Medical Inc.	0.8%	1.0%	3,264,000	+20.9%	$29.8M
HUMHumana Inc	0.8%	0.8%	72,527	-48.7%	$28.8M
ANGOAngioDynamics Inc	0.8%	0.7%	2,198,000	+17.6%	$28.6M
WATWaters Corp.	0.8%	—	75,004	—	$28.1M
VSTMVerastem Inc	0.7%	0.8%	7,024,000	+53.0%	$26.8M
FDMT4d Molecular Therapeutics in	0.7%	—	2,000,000	—	$26.6M
NTLAIntellia Therapeutics Inc	0.7%	—	1,500,000	—	$25.4M
WYNNWynn Resorts Ltd	0.7%	—	261,065	—	$25.3M
TMCITreace Med Concepts Inc	0.7%	—	6,364,000	—	$25.3M
AUTLAutolus Therapeutics PLC	0.7%	0.7%	15,000,000	-5.1%	$24.0M
ARVNArvinas Inc	0.6%	0.7%	2,796,000	+41.4%	$23.2M
MGNXMacrogenics Inc	0.6%	—	5,006,752	—	$23.1M
ANROAlto Neuroscience Inc	0.6%	0.7%	864,000	-5.3%	$22.8M
TOSTToast Inc	0.6%	—	810,830	—	$22.6M
PATHUipath Inc - Class A	0.6%	—	2,000,000	—	$21.7M

What Armistice Capital, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +60.2% /yr; S&P 500 +20.1%
3 years: +23.9% /yr; S&P 500 +20.4%
5 years: +16.1% /yr; S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$3.6B	323
Q1 2026	$3.0B	251
Q4 2025	$4.1B	357
Q3 2025	$3.2B	318
Q2 2025	$2.6B	200
Q1 2025	$3.7B	220
Q4 2024	$4.3B	227
Q3 2024	$3.8B	254
Q2 2024	$3.8B	250
Q1 2024	$3.8B	333
Q4 2023	$3.8B	290
Q3 2023	$3.4B	250

Questions about Armistice Capital, LLC's portfolio

What stocks does Armistice Capital, LLC own?

Armistice Capital, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 323 positions worth $3.6B. The largest are Madrigal Pharmaceuticals Inc (MDGL) at 4.3%, Supernus Pharmaceuticals (SUPN) at 3.4%, Cytokinetics Inc (CYTK) at 2.8%, Incyte Corp (INCY) at 2.8% and Neurocrine Biosciences Inc (NBIX) at 2.5%.

What did Armistice Capital, LLC buy last quarter?

In Q2 2026, Armistice Capital, LLC added Regeneron Pharmaceuticals (REGN) (+148.6% shares), Cytokinetics Inc (CYTK) (+57.1% shares) and Verastem Inc (VSTM) (+53.0% shares), compared with its Q1 2026 filing.

What did Armistice Capital, LLC sell last quarter?

In Q2 2026, Armistice Capital, LLC cut from its top 50 Avanos Med Inc (AVNS), cut from its top 50 Alibaba Group Hldg Ltd (BABA), cut from its top 50 Medline Inc (MDLN), cut from its top 50 Kalvista Pharmaceuticals Inc (KALV), cut from its top 50 Datadog Inc (DDOG), Travere Therapeutics Inc (TVTX) (-67.9% shares), Immunovant Inc (IMVT) (-51.3% shares) and Humana Inc (HUM) (-48.7% shares), compared with its Q1 2026 filing.

How has Armistice Capital, LLC's portfolio performed?

A portfolio copying Armistice Capital, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +23.9% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +60.2% against +20.1%. Over 5 years: +16.1% a year against +11.6%.

When is Armistice Capital, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Armistice Capital, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Armistice Capital, LLC manage?

Armistice Capital, LLC reported $4.7B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $3.6B.